66 related articles for article (PubMed ID: 18386224)
21. Epidermal Growth Factor Receptor Inconsistency by Immunohistochemistry Method Using Different Monoclonal Antibodies in Colorectal Cancer Patients.
Fan CC; Wang TY; Kung CM
Clin Lab; 2015; 61(11):1635-41. PubMed ID: 26731987
[TBL] [Abstract][Full Text] [Related]
22. L-Lactate dehydrogenase B may be a predictive marker for sensitivity to anti-EGFR monoclonal antibodies in colorectal cancer cell lines.
Nagamine A; Araki T; Nagano D; Miyazaki M; Yamamoto K
Oncol Lett; 2019 May; 17(5):4710-4716. PubMed ID: 30944657
[TBL] [Abstract][Full Text] [Related]
23. EGFR-Based Targeted Therapy for Colorectal Cancer-Promises and Challenges.
Janani B; Vijayakumar M; Priya K; Kim JH; Prabakaran DS; Shahid M; Al-Ghamdi S; Alsaidan M; Othman Bahakim N; Hassan Abdelzaher M; Ramesh T
Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455247
[TBL] [Abstract][Full Text] [Related]
24. EGFR IHC score for selection of cetuximab treatment: Ready for clinical practice?
Früh M; Pless M
Transl Lung Cancer Res; 2012 Jun; 1(2):145-6. PubMed ID: 25806170
[No Abstract] [Full Text] [Related]
25. Correction to "Cetuximab-Polymersome-Mertansine Nanodrug for Potent and Targeted Therapy of EGFR-Positive Cancers".
Yue S; Zhang Y; Wei Y; Haag R; Sun H; Zhong Z
Biomacromolecules; 2022 Dec; 23(12):5373-5374. PubMed ID: 36351000
[No Abstract] [Full Text] [Related]
26. Inhibition of EZH2 and EGFR produces a synergistic effect on cell apoptosis by increasing autophagy in gastric cancer cells.
Yang Y; Zhu F; Wang Q; Ding Y; Ying R; Zeng L
Onco Targets Ther; 2018; 11():8455-8463. PubMed ID: 30555238
[TBL] [Abstract][Full Text] [Related]
27. Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment.
Korphaisarn K; Chou CK; Xia WY; Clarke CN; Katkhuda R; Davis JS; Raghav KP; Liao HW; Wu JY; Menter DG; Maru DM; Hung MC; Kopetz S
Am J Cancer Res; 2017; 7(12):2587-2599. PubMed ID: 29312811
[TBL] [Abstract][Full Text] [Related]
28. siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells.
Yuan HH; Yang YN; Zhou JH; Li YJ; Wang LY; Qin JW; Liu T; Li ZZ; Zhou QX; Wei XL; Zhang TT; Huang P; Zhang WJ; Liu L; Du XX; Han Y
Oncotarget; 2017 Aug; 8(32):52584-52593. PubMed ID: 28881753
[TBL] [Abstract][Full Text] [Related]
29.
Chiadini E; Scarpi E; Passardi A; Calistri D; Valgiusti M; Saragoni L; Zoli W; Amadori D; Ulivi P
Oncol Lett; 2015 Mar; 9(3):1432-1438. PubMed ID: 25663927
[TBL] [Abstract][Full Text] [Related]
30. High plasma fibrinogen is correlated with poor response to trastuzumab treatment in HER2 positive breast cancer.
Liu YL; Lu Q; Liang JW; Xia Y; Zhang W; Hu BQ; Shang FF; Ji YR; Wang J; Wang Q; Liang B
Medicine (Baltimore); 2015 Feb; 94(5):e481. PubMed ID: 25654390
[TBL] [Abstract][Full Text] [Related]
31. Cliques for the identification of gene signatures for colorectal cancer across population.
Pradhan MP; Nagulapalli K; Palakal MJ
BMC Syst Biol; 2012; 6 Suppl 3(Suppl 3):S17. PubMed ID: 23282040
[TBL] [Abstract][Full Text] [Related]
32. A Miniaturized Ligand Binding Assay for EGFR.
Schwenk JM; Poetz O; Zeillinger R; Joos TO
Int J Proteomics; 2012; 2012():247059. PubMed ID: 22577549
[TBL] [Abstract][Full Text] [Related]
33. Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma.
Schutt C; Bumm K; Mirandola L; Bernardini G; Cunha N; Tijani L; Nguyen D; Cordero J; Jenkins MR; Cobos E; Kast WM; Chiriva-Internati M
Int Rev Immunol; 2012 Feb; 31(1):22-42. PubMed ID: 22251006
[TBL] [Abstract][Full Text] [Related]
34. Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping.
Arcila M; Lau C; Nafa K; Ladanyi M
J Mol Diagn; 2011 Jan; 13(1):64-73. PubMed ID: 21227396
[TBL] [Abstract][Full Text] [Related]
35. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.
Ferris RL; Jaffee EM; Ferrone S
J Clin Oncol; 2010 Oct; 28(28):4390-9. PubMed ID: 20697078
[TBL] [Abstract][Full Text] [Related]
36. Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients.
Andrade Filho PA; López-Albaitero A; Gooding W; Ferris RL
J Immunother; 2010 Jan; 33(1):83-91. PubMed ID: 19952953
[TBL] [Abstract][Full Text] [Related]
37. Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer.
García-Sáenz JA; Sastre J; Díaz-Rubio García E
Clin Transl Oncol; 2009 Nov; 11(11):737-47. PubMed ID: 19917537
[TBL] [Abstract][Full Text] [Related]
38. The effects of DNA formulation and administration route on cancer therapeutic efficacy with xenogenic EGFR DNA vaccine in a lung cancer animal model.
Lai MD; Yen MC; Lin CM; Tu CF; Wang CC; Lin PS; Yang HJ; Lin CC
Genet Vaccines Ther; 2009 Jan; 7():2. PubMed ID: 19178753
[TBL] [Abstract][Full Text] [Related]
39. EGFR-targeted therapy in colorectal cancer: does immunohistochemistry deserve a role in predicting the response to cetuximab?
Valentini AM; Pirrelli M; Caruso ML
Curr Opin Mol Ther; 2008 Apr; 10(2):124-31. PubMed ID: 18386224
[TBL] [Abstract][Full Text] [Related]
40. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
